LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
Lindis Biotech GmbH / Key word(s): Regulatory Approval LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES 13.02.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLYLINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER
UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE EXCLUSIVE RIGHTS TO BRING CATUMAXOMAB TO MARKET AND TO LEAD ALL ACTIVITIES TO LAUNCH CATUMAXOMAB ACROSS EUROPE
THIS MARKS ANOTHER MILESTONE FOR PHARMANOVIA, AS IT DEEPENS ITS FOOTPRINT WITHIN SPECIALTY PHARMACEUTICALS
MUNICH, GERMANY, AND BASILDON, UK, 13 February 2025LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline in immuno-oncology, and Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, today announced that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.Under a licensing agreement, LINDIS has granted Pharmanovia the exclusive rights to bring catumaxomab to market and spearhead its launch across Europe.Catumaxomab, a first-in-class therapeutic, is specifically designed to treat malignant ascites in adults with certain types of cancer (epithelial cellular adhesion molecule (EpCAM)-positive carcinomas) who are not eligible for other systemic anticancer therapies. Malignant ascites is a serious complication of advanced-stage cancers, characterised by the buildup of fluid in the abdomen, causing significant discomfort and severely impacting quality of life. The condition leads to considerable symptoms such as abdominal distension, pain, shortness of breath, fatigue, and fever.Stephen Deacon, Chief Scientific Officer at Pharmanovia commented; 'This European Commission approval of catumaxomab is a significant milestone for people living with malignant ascites.Catumaxomab represents a novel therapeutic approach to this challenging condition. By targeting tumour cells and harnessing the power of the patient's own immune system, we aim to improve quality of life for those living with malignant ascites in Europe."Pharmanovia CEO, Dr. James Burt, highlighted the broader implications of the approval; 'This approval not only brings a much-needed treatment to people with malignant ascites but also exemplifies Pharmanovia's commitment to deepening our footprint within the specialty pharmaceutical sector. We are dedicated to delivering innovative and improved medicines to people in need, and this approval reinforces our position as a leader in providing access to essential therapies."Dr. Horst Lindhofer, Chief Executive Officer of Lindis Biotech, added: 'We are delighted to receive marketing approval for catumaxomab. The approval highlights its potential to address the significant medical and treatment challenges faced by patients with malignant ascites. These individuals often endure invasive procedures like paracentesis, which carry risks of complications and severely impact their quality of life. Partnering with Pharmanovia to support commercialization, we are committed to ensuring that this groundbreaking therapy becomes accessible to all patients who can benefit from it.'-Ends-Notes to editorsAbout PharmanoviaPharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences.With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.Lindis BiotechLindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases.About CATUMAXOMABCatumaxomab was originally granted marketing authorisation under the brand name Removab in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The product has not been marketed since 2014 and on 2 June 2017 the product was withdrawn from the EU due to commercial reasons.On 17th October Lindis Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) with the brand name KORJUNY®.Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body's immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect. ,The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial cancer) and is also known as a marker on tumor initiating cancer stem cells – a main driver of metastasis. Therefore, it is a promising approach for targeted treatment of various carcinomas.For more information please contact: Pharmanovia Alison Dyson Director of Communications, Pharmanovia Tel.: 07912887250 E-Mail: orLINDIS Biotech GmbH Dr. Horst Lindhofer CEO E-Mail: Website:Media inquiries MC Services AG Anne Hennecke Tel.: +49 (0) 211-529-252-22 E-Mail:References Korjuny | European Medicines Agency (EMA) (2024) European Medicines Agency (EMA). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny (Accessed: 11 December 2024). Ascites and Cancer - Side Effects (2024) Cancer.gov. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/ascites#signs-and-symptoms-of-ascites (Accessed: 11 December 2024). Atanackovic et al., Human Vaccines & Immunotherapeutics 9:12, 1–10; 2013
13.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Zelensky calls on West to slash Russian oil price cap in half as strikes on Ukraine escalate
The price cap on Russian oil should be cut from $60 to $30 per barrel in order to pressure Moscow to declare a ceasefire, President Volodymyr Zelensky said in his evening address on June 10. Zelensky's comments come after the European Commission unveiled its 18th package of sanctions against Russia, including a proposed reduction in the oil price cap from $60 to $45 per barrel. The proposed EU sanctions are a step in "the right direction," Zelensky said, but stronger measures are needed. "Russia's ability to continue the war is equal to its ability to sell its oil and bypass financial barriers," the president said. "That is why it is necessary ... to do everything possible to keep the price of Russian oil lower than they can withstand. Each of the partners knows what price cap is needed — $30, no higher. Such a price level will mean real pressure on Russia – they should be forced to seek peace." The current price cap on Russian oil was introduced by the Group of Seven (G7) and EU in December 2022 as a mechanism to limit the Kremlin's ability to finance the full-scale war in Ukraine. The measure bans Western companies from shipping, insuring, or otherwise servicing Russian oil sold above $60 per barrel. The EU planned to discuss further cuts to the price cap at a G7 summit in May, but the U.S. reportedly blocked the proposal, according to the Financial Times (FT). EU Commission President Ursula von der Leyen said on June 10 that the amendments to the price cap proposed in the new sanctions package will be discussed at the G7 summit to be held on June 15-17. Zelensky called the EU's proposed cap of $45-per-barrel a "compromise price." "Enough compromises with Russia. Every such compromise is a postponement of peace. We are asking for a real reduction in the price of Russian oil, which would bring us closer to ending the war," he said. Russia's attacks on Ukraine are escalating, Zelensky said, necessitating the urgent need for stronger international pressure and tightened economic restrictions. "It is vital that there is no silence in response to the Russian escalation, and it is obvious that there is an escalation," he said. "Russia has been steadily increasing the number of lethal weapons in strikes for months now." The president's comments come after Russia launched one of the largest aerial attacks against Kyiv throughout the full-scale war. The night before, Ukrainian air defense forces shot down 479 Russian drones and missiles in a record-breaking strike. Read also: As Russia inches closer to Dnipropetrovsk Oblast, new Ukrainian region might soon be at war We've been working hard to bring you independent, locally-sourced news from Ukraine. Consider supporting the Kyiv Independent.
Yahoo
an hour ago
- Yahoo
Negative Rates Return to Switzerland as U.S. Faces Higher Yields. What Does it Mean for Bitcoin?
As President Donald Trump's trade war threatens to upend the global economy, an interesting divergence has emerged that could potentially grease the bitcoin BTC bull run. The divergence in consideration is the elevated yields on U.S. Treasury notes that threaten to compound the fiscal issues, and the renewed negative flip in yields on Swiss government bonds. According to data source Swiss government bonds with maturities of up to five years offered negative yields at press time, with the two-year yield at -17.8 basis points. On the contrary, similar-duration Treasury notes offered yields over 4%. The divergence is the bond market's way of telling us that the trade war will have different impacts on various countries, depending on their trade profiles. Those running trade surpluses, such as several European countries and China, will face disinflation or an outright deflation, while countries like the U.S., which import more than they export, will see an increase in price pressures. The specter of deflation in European nations and China could put pressure on their central banks to ease monetary policy aggressively, likely leading to increased capital deployment into alternative investments like bitcoin. Both the Swiss National Bank and the European Central Bank have already cut rates in recent months. Meanwhile, analysts have said that higher yields in the U.S. and the record public debt could accelerate the shift away from U.S. assets and into alternative assets. "The last time this happened [Swiss yields turned negative in late 2019], it preceded coordinated global easing, repo market seizures, and ultimately pandemic-era QE. Now, it likely reflects a mix of deflationary pressure, eurozone contagion risks, and capital rotating into monetary sovereignty safe havens amid sovereign stress elsewhere," pseudonymous analyst EndGame Macro said on X. It's worth noting that bitcoin's 2020-2021 bull run from $5,000 to over $60,000 was characterized by a record amount of negative-yielding government debt worldwide. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
France's Mistral launches Europe's first AI reasoning model
By Supantha Mukherjee and Kenrick Cai PARIS (Reuters) -Mistral on Tuesday launched Europe's first AI reasoning model, which uses logical thinking to create a response, as it tries to keep pace with American and Chinese rivals at the forefront of AI development. The French startup has attempted to differentiate itself by championing its European roots, winning the support of French President Emmanuel Macron, as well as making some of its models open source in contrast to the proprietary offerings of OpenAI or Alphabet's Google. Mistral is considered Europe's best shot at having a home-grown AI competitor, but has lagged behind in terms of market share and revenue. Reasoning models use chain-of-thought techniques - a process that generates answers with intermediate reasoning abilities when solving complex problems. They could also be a promising path forward in advancing AI's capabilities as the traditional approach of building ever-bigger large language models by adding more data and computing power begins to hit limitations. For Mistral, which was valued by venture capitalists at $6.2 billion, an industry shift away from "scaling up" could give it a window to catch up against better capitalized rivals. China's DeepSeek broke through as a viable competitor in January through its low-cost, open-sourced AI models, including one for reasoning. OpenAI was the first to launch its reasoning models last year, followed by Google a few months later. Meta, which also offers its models open-sourced, has not yet released a standalone reasoning model, though it said its latest top-shelf model has reasoning capabilities. Mistral is launching an open-sourced Magistral Small model and a more powerful version called Magistral Medium for business customers. "The best human thinking isn't linear - it weaves through logic, insight, uncertainty, and discovery. Reasoning language models have enabled us to augment and delegate complex thinking and deep understanding to AI," Mistral said. American companies have mostly kept their most advanced models proprietary, though a handful, such as Meta, has released open-source models. In contrast, Chinese firms ranging from DeepSeek to Alibaba have taken the open-source path to demonstrate their technological capabilities. Mistral Small is available for download on Hugging Face's platform and can reason in languages including English, French, Spanish, Arabic and simplified Chinese.
